Financial Perspectives’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Financial Perspectives’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-490	Closed	-$338	–	642
2020 Q4	$338	Buy	490 +65	+15%	+$138	﹤0.01%	585
2020 Q3	$956	Hold	425	–	–	﹤0.01%	531
2020 Q2	$1.52K	Hold	425	–	–	﹤0.01%	498
2020 Q1	$1.61K	Buy	425 +65	+18%	+$214	﹤0.01%	465
2019 Q4	$1.08K	Buy	+360	New	+$936	﹤0.01%	481

Other funds holding BMY.RT

JCI

Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return

TNB

Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return

WAM

Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return

IAIM

International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Financial Perspectives's BMY.RT Position: Q1 2021 in Review

Financial Perspectives sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 490 shares — an estimated $338 sold.

Financial Perspectives first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $1.61K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

Financial Perspectives reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
Financial Perspectives sold 490 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $338.
Financial Perspectives first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
Financial Perspectives's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $1.61K in Q1 2020.
12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Financial Perspectives's 13F filing for Q1 2021, filed 10 Jan 2024.